Reaction

Pharyngeal Inflammation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,193 reports · 28 co-occurring drugs

As of the last recalculation, Pharyngeal Inflammation appears in 1,193 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is CETUXIMAB (PRR 45.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Cetuximab7745.845.9
Granisetron Hydrochloride1932.232.3
Granisetron1830.430.4
Dimenhydrinate1829.930.0
Thiotepa1222.122.2
Cytarabine5115.415.4
Minocycline913.613.6
Filgrastim2712.812.8
Melphalan1612.412.4
Cefepime1012.312.3
Melphalan Hydrochloride1712.012.0
Cefepime Hydrochloride1010.910.9
Cisplatin4610.610.7
Busulfan910.010.1
Pegaspargase710.010.0
Etoposide399.59.5
Pemetrexed119.09.0
Belimumab168.98.9
Bleomycin Sulfate58.58.5
Irinotecan Hydrochloride68.28.2
Mometasone Furoate And Formoterol Fumarate Dihydrate77.97.9
Capecitabine407.97.9
Docetaxel Anhydrous297.77.7
Docetaxel297.77.7
Fluorouracil Cream, 0.5%327.57.5
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate76.86.8
Aflibercept73.93.9
Nirmatrelvir And Ritonavir72.32.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.